Kim JH, Yoon S, Lee DH, et al. - In this study, the clinical usefulness of next‐generation sequencing (NGS) for the detection of genetic alterations and its implications on the treatment of lung adenocarcinoma in real‐world practice was explored. Between March 2017 and October 2018, researchers examined data of 391 patients with lung adenocarcinoma who had undergone NGS. They used formalin‐fixed, paraffin‐embedded archival samples for performing NGS targeting 382 genes, including all exons of 199 genes, 184 hotspots, and the partial introns of 8 genes often rearranged in cancer. They carried out survival analysis for stage IV disease. The results showed that AMs could be comparably detected using NGS. According to NGS outcomes, a suitable targeted therapy can be selected, which may improve survival in patients with lung adenocarcinoma. The outcomes suggested that this NGS‐based approach is beneficial in real‐world practice to provide guidance when selecting targeted therapy.